Study Reveals How p53-Mutant Tumors Hide From T Cells

Cancer cells carrying mutations in the tumor-suppressor protein p53 can conceal those mutations from T cells by failing to process them into stable, visible targets, according to a peer-reviewed study led by Dana-Farber Cancer Institute and Harvard Medical School investigators and published in Immunity. The experiments identified several distinct escape mechanisms and showed that blocking the enzyme ERAP1 restored recognition of one class of p53-mutant cancer cells by p53-specific T cells in laboratory models. The authors propose a broader strategy, called “immunopeptidome shifting,” that would alter which peptides tumor cells display, potentially exposing new targets for immune attack.

The research provides a mechanistic foundation for that approach, but it has not yet demonstrated that a drug can convert cold human tumors into hot tumors in patients. T cells do not read a tumor’s DNA directly. Instead, they inspect small protein fragments, or peptides, presented on the cell surface by human leukocyte antigen, or HLA, molecules.

The complete collection of these displayed fragments is known as the immunopeptidome, effectively a molecular window that determines which targets a T cell can detect. A mutation identified by genome sequencing may therefore have little practical value as an immunotherapy target if its peptide is never generated, cannot be displayed by the patient’s HLA molecules, or disappears too quickly from the surface. Even a highly sensitive T-cell receptor needs a sufficiently stable target on the cancer cell before it can respond reliably.

The p53 system is a particularly important test case because mutations in TP53, the gene encoding p53, occur in roughly half of all human cancers. Many TP53 mutations arise early in tumor development and are inherited by nearly every cancer cell as the tumor grows. Such “truncal” mutations have consequently been viewed as unusually attractive immunotherapy targets because, in principle, attacking one could strike the entire tumor rather than only one branch.

The new study shows why that promise is often not realized, even when the mutation is present and a capable T-cell receptor exists. Using an ultrasensitive mass-spectrometry platform that physically measured peptides displayed on tumor cells, the investigators found that p53 was much less visible to T cells than DNA sequences or computational predictions alone would suggest. Of 175 predicted wild-type p53 peptide candidates examined across relevant HLA molecules, only five were robustly detected.

Many common cancer-causing p53 “hotspot” mutations occurred in regions that were poorly processed and therefore failed to generate any detectable surface targets. These observations show that mutation status is only the first step in a longer chain: a candidate must be processed into a peptide, loaded onto an appropriate HLA molecule, retained long enough on the surface, and recognized by a receptor able to respond at the low target densities found in cancer cells. Patient tumors exposed an additional escape route.

Some tumors carrying potentially powerful p53 targets lacked the HLA molecule required to display those targets. A separate analysis of the p53 I195F mutation revealed that high activity of the enzyme ERAP1 in cancer cells acted like an overzealous molecular trimming machine. It destroyed an otherwise strongly immunogenic p53 fragment before the peptide could be presented to T cells.

Deleting ERAP1, or blocking it with an inhibitor, restored recognition of those cancer cells by p53-specific T cells in laboratory experiments. The result establishes ERAP1-dependent peptide destruction as a reversible mechanism in the tested system, not as an established cancer treatment in people. The common p53 R175H mutation exposed a different weakness.

Engineered T-cell therapies directed against this mutation are already being pursued in clinical studies, according to the research report. The investigators identified highly sensitive T-cell receptors capable of responding to extremely sparse amounts of the mutant p53 target. However, the mutant peptide bound its HLA molecule so weakly that the resulting complex was unstable and short-lived.

The immune receptor was capable, but the molecular target was poor. T-cell activation and cancer-cell killing were consequently much weaker than they were against a more stable p53 target, indicating that strengthening T cells alone may not overcome every barrier to recognition. The authors call their proposed solution an “immunopeptidome shift.” Rather than relying only on the peptides a tumor naturally displays, drugs could deliberately alter antigen presentation so that cancer cells reveal additional peptide targets.

The study points to several possible routes: ERAP1 inhibitors; small molecules that bind to HLA molecules and change which peptides can fit; and drugs that alter RNA splicing, thereby changing which protein fragments are produced. If delivered selectively to tumors, such agents might create a broader set of targets for cytotoxic T-cell populations. The proposed goal is to make an immunologically inconspicuous tumor attract and activate multiple T-cell populations that recognize different displayed peptides, the intended meaning of turning a “cold” tumor “hot.”

The strategy could also make immune escape more difficult. Cancers can evade therapy directed against a single target by editing that peptide out of their surface display. A drug-induced immunopeptidome shift could instead expose several targets at once and recruit a polyclonal T-cell response, making the tumor less dependent on any one molecular weakness.

The authors suggest that this approach might complement checkpoint inhibitors, therapeutic vaccines or engineered T-cell therapies rather than replace them. The study did not test these clinical combinations, however, and the broader therapeutic value of shifting antigen display remains a hypothesis that requires further evaluation. The multidisciplinary research combined ultrasensitive immunopeptidomics, human tumor genomics, X-ray crystallography, engineered human T cells, single-molecule T-cell-receptor measurements and functional tumor-cell killing assays.

Investigators from Dana-Farber and Harvard Medical School were joined by scientists from Vanderbilt University, Argonne National Laboratory, Boston Children’s Hospital and collaborating institutions. By connecting mutations with peptide processing, HLA presentation, molecular stability and cellular immune recognition, the team addressed a limitation of computational prediction: a software model can nominate candidate peptides, but it cannot by itself establish that those peptides are processed, displayed and retained in a form that real T cells can recognize. The study also distinguishes naturally occurring escape mechanisms from the experimentally reversed ERAP1 mechanism, rather than treating all p53 mutations as equally visible or equally resistant to immune targeting.

For neoantigen drug development, the findings establish a more demanding standard for selecting targets. A mutation predicted from tumor sequencing should not automatically be assumed to support immunotherapy. Researchers must determine whether the relevant peptide is processed, displayed by the patient’s HLA molecules, sufficiently stable on the cell surface, and recognizable by a T-cell receptor sensitive enough to operate at the very low target densities typical of cancer cells.

The demonstrated result is narrower but concrete: p53-mutant tumors can suppress desirable immune targets through multiple mechanisms, and inhibiting ERAP1 can restore T-cell recognition in the laboratory. The broader proposal is to change the cancer’s molecular window display so that previously hidden targets become visible to an existing or engineered immune response.

Subject of Research: Mechanisms of p53 neoantigen processing and T-cell escape in cancer

Article Title: Making invisible cancers visible: Study suggests a new route to turn ‘cold’ tumors ‘hot’

Article References: Making invisible cancers visible: Study suggests a new route to turn ‘cold’ tumors ‘hot’. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: p53 mutations, cancer immunology, T cells, immunopeptidome, antigen presentation, ERAP1, HLA molecules, neoantigens, cold tumors, immunotherapy, Making, invisible